INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Capricor Therapeutics, Inc. and its officers or directors [1]. Group 1: Company Developments - On May 5, 2025, Capricor announced that the FDA confirmed its intent to hold an advisory committee meeting regarding the Biologics License Application for deramiocel, a treatment for Duchenne muscular dystrophy cardiomyopathy [3]. - Following this announcement, Capricor's stock price dropped by $3.00 per share, or 29.13%, closing at $7.30 per share on May 6, 2025 [4]. - On June 20, 2025, it was reported that the FDA canceled the advisory committee meeting due to concerns about the drug's efficacy and safety, leading to a further decline in Capricor's stock price by $3.68 per share, or 30.82%, closing at $8.26 per share [4]. Group 2: Legal and Investigative Actions - Pomerantz LLP, a firm specializing in corporate, securities, and antitrust class litigation, is leading the investigation into Capricor's practices [5]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct [5].